AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. common stock between August 6, 2024 and May 27, 2025.  Tempus ...